JPRN-jRCT2080221859未知3 期
A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension
ovartis Pharma K.K.0 个研究点目标入组 34 人开始时间: 2012年7月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*Satisfy office msSBP>=180 mmHg or office msDBP>=110 mmHg at baseline.
排除标准
- •*Patients show msSBP >=220 mmHg and/or msDBP >=120 mmHg.
- •*History of angioedema, drug-related or otherwise, as reported by the patient.
- •*Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.
- •*Patients have significant cardiovascular co-morbidities.
- •*Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.
- •Other protocol defined inclusion/exclusion criteria may apply.
研究者
相似试验
未知
3 期
Open Label Study of Treatment With LCZ696 in Hypertensive Patients With Renal DysfunctioHypertensive Patients With Renal DysfunctionJPRN-jRCT2080221812ovartis Pharma K.K.28
已完成
不适用
[18F]THK-5351 PET Study of Normal, Mild Cognitive Impairment, Alzheimer’s Disease and Other Neurodegenerative DiseaseKCT0001785Asan Medical Center180
进行中（未招募）
1 期
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyEUCTR2016-005023-92-Outside-EU/EEASarepta Therapeutics, Inc.40
进行中（未招募）
1 期
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyEUCTR2016-005024-28-Outside-EU/EEASarepta Therapeutics, Inc.24
进行中（未招募）
不适用
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccineovartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.EUCTR2014-004903-63-Outside-EU/EEAovartis Vaccines and Diagnostics Inc.825